|
Jul 29
|
Telix H1 2025 Results: Investor Webcast Notification
|
|
Jul 22
|
Telix Pharmaceuticals (ASX:TLX) Confirms 2025 Revenue Forecast Between A$770 Million To A$800 Million
|
|
Jul 22
|
MTTI Announces Dr. Danielle Meyrick to Lead Medical Team
|
|
Jul 22
|
Telix Reports $204M Revenue, Up 63% YOY
|
|
Jul 21
|
Exploring Three High Growth Tech Stocks in Australia
|
|
Jul 17
|
Top ASX Growth Stocks With High Insider Ownership In July 2025
|
|
Jun 29
|
Telix Pharmaceuticals (TLX) Announces That US FDA Approves Label Expansion for Illuccix
|
|
Jun 4
|
Telix Pharmaceuticals (ASX:TLX) Gains Portugal Approval for Illuccix in Prostate Cancer Detection
|
|
Jun 3
|
Telix Manufacturing Solutions (TMS) Established in Yokohama, Japan
|
|
Jun 3
|
Telix Investor Day in New York City on June 11, 2025: Presenting KOLs
|
|
Apr 22
|
Telix Reports US$186M Q1 Revenue, Up 62% YOY
|
|
Feb 13
|
Telix to Showcase Urology Pipeline at Upcoming ASCO Genitourinary Cancers Symposium (ASCO GU 2025)
|
|
Feb 12
|
Illuccix® Approved in the United Kingdom
|
|
Feb 11
|
Is Telix Pharmaceuticals Limited (TLX) the Best Long Term ASX Stock to Buy Now?
|
|
Dec 30
|
NOBLE Registry Update: TLX599-CDx PSMA SPECT Imaging of Prostate Cancer Published in EJNMMI Reports
|
|
Dec 29
|
Telix Files TLX250-CDx (Zircaix®) BLA for Kidney Cancer Imaging
|
|
Oct 4
|
Health Canada Approves Label Expansion for Telix’s Illuccix® to Include Patient Selection for PSMA-Targeted Therapy
|
|
Oct 3
|
First Patient Dosed in Phase II 'CA-NINE' Trial of TLX250-CDx for Detection of Recurrent Kidney Cancer After Surgery
|
|
Jul 29
|
Expanded Access Program Opens in the U.S. for TLX101-CDx, Telix’s Investigational Glioma (Brain Cancer) Imaging Agent
|
|
Jul 24
|
FDA Accepts Telix NDA for New Prostate Cancer Imaging Agent
|